Stafford, Texas – September 10, 2025 — Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for…
FDA Fast Tracks GLSI-100 for HER2-Positive Breast Cancer Recurrence Prevention
